WEREWOLF THERAPEUTICS, INC.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Operating Activities | ||||||
| Net Income | $-60.8M | $-70.5M | $-37.4M | $-53.8M | $-50.0M | $-15.0M |
| Depreciation & Amortization | — | — | — | — | — | — |
| Depreciation | $1.6M | $1.8M | $1.8M | $1.1M | $216.0K | $150.0K |
| Amortization | — | — | — | — | — | — |
| Stock-Based Compensation | $6.2M | $8.8M | $8.0M | $7.4M | $4.1M | $632.0K |
| Net Cash from Operating Activities | $-60.3M | $-56.2M | $-32.6M | $-40.6M | $-42.9M | $-18.6M |
| Investing Activities | ||||||
| Capital Expenditures | $0 | $254.0K | $769.0K | $3.6M | $498.0K | $560.0K |
| Business Acquisitions | — | — | — | — | — | — |
| Net Cash from Investing Activities | $0 | $-254.0K | $-769.0K | $-3.6M | $-498.0K | $-560.0K |
| Financing Activities | ||||||
| Dividends Paid | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — |
| Net Cash from Financing Activities | $6.0M | $13.1M | $58.4M | $15.9M | $109.4M | $93.9M |
| Net Change in Cash | $-54.3M | $-43.4M | $25.0M | $-28.3M | $66.1M | $74.7M |
| Free Cash Flow | $-60.3M | $-56.4M | $-33.4M | $-44.2M | $-43.4M | $-19.2M |